Research Brief
Tesamorelin: Chemical Properties
24 Citacoes PubMedRevisado por EspecialistasCertificado GMPUltima Revisao: julho de 2026
Propriedades Quimicas
| Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular Weight | 5135.9 Da |
| Synonyms | TH9507, Egrifta, Egrifta SV, Egrifta WR, Tesamorelin acetate, [hexenoyl-trans-3-Tyr1]hGRF(1-44)NH₂, Hex-hGRF |
| Cas Number | 218949-48-5 (free base); 901758-09-6 (acetate) |
| Sequence | hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH₂ (44 aa) |
| Pubchem Cid | 16137828 |
| Monoisotopic Mass | N/A |
| Polar Area | N/A |
| Complexity | N/A |
| X Log P | N/A |
| Heavy Atom Count | N/A |
| H Bond Donor Count | N/A |
| H Bond Acceptor Count | N/A |
| Rotatable Bond Count | N/A |
Identificadores
| Pubchem Cid | 16137828 |
| Inchi Key | VQFDKKWXORFBDI-VAVVJCQZSA-N |
| Inchi | InChI=1S/C220H364N72O67S/... (44-residue peptide — see PubChem CID 16137828) |
| Smiles Isomeric | See PubChem CID 16137828 for full stereochemical SMILES |
| Smiles Canonical | See PubChem CID 16137828 for full canonical SMILES |
| Iupac Name | Tesamorelin — trans-3-hexenoyl-modified GHRH(1-44)-NH₂ (see PubChem CID 16137828) |
Referencias
- Falutz J, Allas S, Kotler D, et al. A controlado por placebo, dose-ranging study of a hormonio do crescimento releasing factor in HIV-infected sujeitos de estudo with abdominal fat accumulation. AIDS, 19(12), 1279-87, 2005.
- Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and tolerability evaluation of TH9507, a human hormonio do crescimento-releasing factor analogue. Basic Clin Pharmacol Toxicol, 100(1), 49-58, 2007.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a hormonio do crescimento-releasing factor in sujeitos de estudo with HIV. N Engl J Med, 357(23), 2359-70, 2007.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507) in HIV-infected sujeitos de estudo with excess abdominal fat: pooled analysis of two Phase 3 trials. J Clin Endocrinol Metab, 95(9), 4291-304, 2010.
- Wang Y, Tomlinson B. Tesamorelin, a human hormonio do crescimento releasing factor analogue. Expert Opin Investig Drugs, 18(3), 303-10, 2009.
- Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev compound Discov, 10(2), 95-6, 2011.
- Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a hormonio do crescimento-releasing hormone analog on endogenous GH pulsatility and sensibilidade a insulina in healthy men. J Clin Endocrinol Metab, 96(1), 150-8, 2011.
- Dhillon S. Tesamorelin: a review of its use no(a) management of HIV-associated lipodystrophy. Drugs, 71(8), 1071-91, 2011.
- Spooner LM, Olin JL. Tesamorelin: a hormonio do crescimento-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother, 46(2), 240-7, 2012.
- Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associado(a) com an melhorou metabolic profile in HIV-infected sujeitos de estudo receiving tesamorelin. Clin Infect Dis, 54(11), 1642-51, 2012.
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty doenca hepatico(a)a in HIV: a randomised, duplo-cego, multicentre trial. Lancet HIV, 6(12), e821-e830, 2019.
- Adrian S, Scherzinger A, Sanyal A, et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging, 8(3), 154-159, 2019.
- Baker LD, Barsness SM, Borson S, et al. Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults. Arch Neurol, 69(11), 1420-9, 2012.
- Lopez J, Quan A, Budihardjo J, et al. Growth Hormone Improves Nerve Regeneration, Muscle Re-innervation, and Functional Outcomes After Chronic Denervation Injury. Sci Rep, 9(1), 3117, 2019.
- Grinspoon SK, Fourman L, Stanley T, et al. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores: Subanalysis. Open Forum Infect Dis, 12(Suppl 1), 2025.
- Clemmons DR, Miller S, Mamputu JC. tolerability and metabolic effects of tesamorelin in sujeitos de estudo with diabetes tipo 2: A randomizado, controlado por placebo trial. PLoS One, 12(6), e0179538, 2017.
- Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a hormonio do crescimento-releasing factor in obese subjects with reduziu hormonio do crescimento secretion. J Clin Endocrinol Metab, 97(12), 4769-79, 2012.
- Fourman LT, Czerwonka N, Feldpausch MN, et al. Visceral fat reduction with tesamorelin is associado(a) com melhorou liver enzymes in HIV. AIDS, 31(16), 2253-9, 2017.
- Mangili A, Falutz J, Mamputu JC, et al. Predictors of aplicacao em pesquisa response to tesamorelin in HIV-infected sujeitos de estudo with excess abdominal fat. PLoS One, 10(10), e0140358, 2015.
- Lake JE, La K, Erlandson KM, et al. Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity. AIDS, 35(9), 1395-1402, 2021.
- Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK. The Effects of Tesamorelin on Phosphocreatine Recovery in Obese Subjects With Reduced GH. J Clin Endocrinol Metab, 99(1), 338-343, 2014.
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected sujeitos de estudo: a randomizado ensaio clinico. JAMA, 312(4), 380-9, 2014.
- Ellis RJ, Vaida F, Hu K, et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis, 231(5), 1230-1238, 2025.
- Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin in HIV-infected sujeitos de estudo with abdominal fat accumulation: a randomizado controlado por placebo trial with safety extension. J Acquir Immune Defic Syndr, 53(3), 311-22, 2010.
Perguntas de Pesquisa Relacionadas
APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.